DAC
CRSP icon

Dividend Assets Capital’s CRISPR Therapeutics CRSP Stock Holding History

Dividend Assets Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-62
Closed -$4K – 193
2023
Q4 		$4K Hold
62
– – ﹤0.01% 425
2023
Q3 		$3K Hold
62
– – ﹤0.01% 447
2023
Q2 		$3K Hold
62
– – ﹤0.01% 472
2023
Q1 		$3K Hold
62
– – ﹤0.01% 502
2022
Q4 		$3K Hold
62
– – ﹤0.01% 502
2022
Q3 		$4K Hold
62
– – ﹤0.01% 501
2022
Q2 		$4K Hold
62
– – ﹤0.01% 512
2022
Q1 		$4K Buy
62
+28
+82% +$1.76K ﹤0.01% 464
2021
Q4 		$3K Hold
34
– – ﹤0.01% 472
2021
Q3 		$4K Buy
+34
New +$4.27K ﹤0.01% 451

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dividend Assets Capital's CRSP Position: Q1 2024 in Review

Dividend Assets Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 62 shares — an estimated $4K sold.

Dividend Assets Capital first reported a position in CRSP in Q3 2021 and held it in 10 quarters. The position peaked at $4K in Q4 2023. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Dividend Assets Capital reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Dividend Assets Capital sold 62 CRISPR Therapeutics shares in Q1 2024, an estimated $4K.
  • Dividend Assets Capital first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 10 quarters.
  • Dividend Assets Capital's CRISPR Therapeutics position peaked at $4K in Q4 2023.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Dividend Assets Capital's 13F filing for Q1 2024, filed 15 May 2024.